Glioblastoma is the most common and most aggressive primary brain tumor, with an average survival after diagnosis of less than two years, and against which current treatments remain ineffective. In recent years, immunotherapies have given patients renewed hope, albeit with relatively modest success. A team has succeeded in identifying a specific marker on the surface of tumour cells, and in generating immune cells carrying an antibody to destroy them. Furthermore, these cells, called CAR-T cells, appear to be capable of targeting diseased cells in the tumor that do not carry this antigen, while sparing healthy cells.
